Abstract C010: Updates from the Childhood Cancer Predisposition Study: A report from the Consortium for Childhood Cancer Predisposition
Suzanne P. MacFarland, Lisa Diller, Maria Frazer, Junne Kamihara, Uyen Q. Le, Philip Lupo, Luke Maese, David Malkin, Abra Morgan, Kim E. Nichols, Melissa R. Perrino, Sharon E. Plon, Surya Rednam, Jennie Vagher, Christopher C. Porter, Anita VillaniAbstract
Background:
Genetic predisposition contributes to a much higher proportion of cancer in children than previously appreciated. This creates a unique opportunity to develop improved methods to identify children at increased risk for cancer, enable early detection or prevention of tumors, and improve cure rates with decreased morbidity. However, several challenges have impeded successful research and systematic approaches to the care of children with cancer predisposition.
Methods:
We established the Consortium for Childhood Cancer Predisposition (C3P), currently comprised of seven large pediatric institutions in North America. The long-term goal of C3P is to improve outcomes for children with genetic susceptibility to cancer through collaborative research and data sharing. To this end, we have developed the Childhood Cancer Predisposition Study (CCPS), a multicenter registry and biorepository, to achieve three main aims: 1) Establish and maintain the infrastructure for recruitment, participation, collection and sharing of clinical data and biological samples for children with cancer predisposition syndromes (CPS); 2) Define the spectrum of disease in children with CPS and explore the unique characteristics and management approaches of CPS-related tumors compared to their sporadic counterparts; and 3) Evaluate the clinical impact and effectiveness of standard and emerging tumor surveillance strategies.
Results:
The CCPS opened to enrollment in May, 2021 and is currently recruiting at 7 member sites. To date, 702 primary subjects and 196 family members have been enrolled. In total, more than 50 different cancer predisposition diagnoses are represented among participants, including those that are more prevalent, e.g., Li-Fraumeni syndrome (n=86), DICER1 syndrome (n=53), and PTEN Hamartoma Syndrome (n=37), and those which are very rare, e.g., Rothmund-Thomson syndrome (n=2). There is excellent uptake in obtaining samples, with the CCPS Biorepository at Emory University receiving biospecimens from 857 subjects to date, including constitutional DNA (n=721), viably frozen peripheral blood mononuclear cells (n=163), and plasma samples for ctDNA analysis (n= 127).
Conclusions:
C3P has established the infrastructure to facilitate comprehensive collaborative work to improve outcomes for children with cancer predisposition, which represent a wide variety of disorders. Future efforts will include the advancement of innovative strategies to promote recruitment beyond the primary C3P sites, analysis of surveillance outcomes, and the development of additional clinical and biological studies of specific CPS.
Citation Format:
Suzanne P. MacFarland, Lisa Diller, Maria Frazer, Junne Kamihara, Uyen Q. Le, Philip Lupo, Luke Maese, David Malkin, Abra Morgan, Kim E. Nichols, Melissa R. Perrino, Sharon E. Plon, Surya Rednam, Jennie Vagher, Christopher C. Porter, Anita Villani. Updates from the Childhood Cancer Predisposition Study: A report from the Consortium for Childhood Cancer Predisposition [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Bridging Discovery and Clinical Impact in Pediatric Cancer; 2026 Sep 22-25; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_1):Abstract nr C010.